A federal jury in California dominated Friday that Apple should pay medical gadget maker Masimo $634 million for infringing a patent on blood oxygen monitoring know-how.

Reuters reports that the jury discovered that the Apple Watch’s exercise mode and coronary heart fee notification options violated Masimo’s patent.

“This can be a vital win in our ongoing efforts to guard our improvements and mental property, which is essential to our capacity to develop know-how that advantages sufferers,” Masimo mentioned in a statement. “We stay dedicated to defending our IP rights shifting ahead.”

An Apple spokesperson informed Reuters that the corporate plans to attraction the decision, including, “The one patent on this case expired in 2022, and is particular to historic affected person monitoring know-how from many years in the past.”

TechCrunch has reached out to Apple for added remark.

The authorized dispute between Masimo and Apple focuses on pulse oximetry, which makes use of an optical sensor to detect blood circulate. Masimo has accused Apple of hiring away its workers — together with its chief medical officer — and infringing its patents on pulse oximetry know-how. 

The U.S. Worldwide Commerce Fee sided by Masimo in 2023, banning Apple from importing Apple Watches with blood oxygen monitoring options — which is why Apple Watches haven’t supported blood oxygen monitoring lately.

Then Apple introduced in August of this 12 months that it’s introducing a new version of the feature designed to avoid the ban, with blood oxygen readings measured and calculated on the person’s paired iPhone, quite than the Apple Watch itself.

Masimo is suing U.S. Customs and Border Patrol for approving the import of Apple Watches with the brand new blood oxygen implementation, whereas Apple has asked an appeals court to overturn the import ban.

Apple additionally countersued Masimo, winning the statutory minimum payment of $250 when a jury discovered that Masimo had violated Apple design patents.